Huateng Pharmaceutical, a global supplier of pharmaceutical intermediates, offers Moxonidine intermediates 1-[2-[(4,6-Dichloro-2-methylpyrimidin-5-yl)amino]-4,5-dihydroimidazol-1-yl]ethanone (CAS No.: 75438-54-9) for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation.
*The following content is generated by AI and is for reference only.
The chemical compound 1-[2-[(4,6-Dichloro-2-methylpyrimidin-5-yl)amino]-4,5-dihydroimidazol-1-yl]ethanone is a sophisticated heterocyclic molecule of significant interest in medicinal chemistry and drug discovery. Its molecular formula is C₁₀H₁₀Cl₂N₄O, reflecting a complex structure composed of a dichloropyrimidine ring linked via an amino bridge to a dihydroimidazole moiety, which is further substituted with an acetyl group. While specific CAS registry numbers for this exact derivative may vary depending on the precise synthesis route or salt form, it generally falls under the broad category of pyrimidine-based kinase inhibitors. This class of compounds is renowned for its ability to modulate cellular signaling pathways by competitively binding to the ATP-binding site of various protein kinases.
In pharmaceutical research, this molecule serves primarily as a valuable intermediate or lead compound for developing novel therapeutic agents targeting oncological disorders. The presence of the electron-withdrawing chlorine atoms on the pyrimidine ring and the reactive imidazoline core suggests high potential for covalent bonding or strong non-covalent interactions with specific kinase domains, such as those found in EGFR, BRAF, or JAK families. By inhibiting these hyperactive enzymes, researchers aim to halt uncontrolled cell proliferation and induce apoptosis in cancer cells. Furthermore, the structural flexibility allows for extensive Structure-Activity Relationship (SAR) studies, where chemists can modify the acetyl group or the methyl substituent to enhance potency, selectivity, and pharmacokinetic properties like bioavailability and metabolic stability.
Beyond oncology, derivatives of this scaffold are being explored for anti-inflammatory and antiviral applications, given the critical role of kinases in immune response regulation. Although currently utilized mainly within laboratory settings for preclinical screening and mechanistic studies, the optimization of this compound could pave the way for next-generation small-molecule drugs. Its unique architecture offers a promising platform for addressing resistance issues seen in existing therapies, making it a focal point for academic institutions and biotechnology firms dedicated to advancing precision medicine. Continued investigation into its biological profile is essential to fully unlock its clinical potential and translate laboratory findings into effective treatments for patients suffering from difficult-to-manage diseases.